Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
复制标题
DOI：
10.1093/annonc/mdq160
复制
发表时间：
2010-05-01
影响因子：
50.5
通讯作者：
Castiglione, M.
中科院分区：
文献类型：
--
作者：
Cardoso, F.;Senkus-Konefka, E.;Castiglione, M.
乳腺癌是包括发展中国家在内的许多国家女性最常见的癌症。2006年，欧盟的粗发病率为109.8/10万，死亡率为38.4/10万妇女/年。自1990年以来，发病率以每年1.5%的速度递增。由于早期发现和辅助治疗方面的进步，自20世纪90年代初以来，大多数西方国家的乳腺癌死亡率一直在稳步下降。然而，它仍然是女性癌症死亡的主要原因。大约6%的乳腺癌在确诊时是转移性的，5年生存率为21%。根据预后因素，在最糟糕的情况下，高达30%的结节阴性和高达70%的结节阳性乳腺癌将复发。转移性疾病的患病率很高，因为许多妇女与这种疾病一起生活了几年。
Breast cancer is the most common cancer in women in many countries, including developing countries. In 2006, the crude incidence in the European Union was 109.8/100 000, the mortality was 38.4/100 000 women/year. Since 1990 the incidence rate has increased 1.5% annually. Due to advances both in early detection and in adjuvant treatment, mortality rates from breast cancer have been decreasing steadily in most western countries since the early 1990s. However, it is still the leading cause of cancer mortality in women. Approximately 6% of breast cancers are metastatic at diagnosis with a 5-year survival rate of 21%. Depending on prognostic factors, in the worst scenario, up to 30% of node-negative and up to 70% of node-positive breast cancers will relapse. The prevalence of metastatic disease is high because many women live with the disease for several years.